Risk factors for seizures and antiepileptic drug-associated adverse effects in high-grade glioma patients: A multicentre, retrospective study in Hong Kong

Surgical Practice

Volumn 19, Issue 1, 2015, Pages 2-8

  Woo, Peter Yat Ming ^b   Chan, Danny Tat Ming ^a   Chan, Kwong Yau ^b   Wong, Wai Kei ^c   Po, Yin Chung ^c   Kwok, John Ching Kong ^b   Poon, Wai Sang ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b KWONG WAH HOSPITAL   (Hong Kong)

^c PRINCESS MARGARET HOSPITAL   (Hong Kong)

Author keywords

Adverse effect; Aromatic antiepileptic drug; Glioblastoma multiforme; High grade glioma; Seizure prophylaxis

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CARMUSTINE; LOMUSTINE; PHENOBARBITAL; PHENYTOIN; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURGERY; CONTROLLED STUDY; DISEASE DURATION; EPENDYMOMA; FEMALE; FOLLOW UP; GLIOBLASTOMA; GLIOSARCOMA; HONG KONG; HUMAN; INCIDENCE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; POSTOPERATIVE PERIOD; PRESCRIPTION; QUALITY OF LIFE; RETROSPECTIVE STUDY; RISK FACTOR; SEIZURE; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; VERY ELDERLY;

EID: 84920913086     PISSN: 17441625     EISSN: 17441633     Source Type: Journal    
DOI: 10.1111/1744-1633.12102     Document Type: Article

References (29)

1. Lwu S, Hamilton MG, Forsyth PA, Cairncross JG, Parney IF. Use of peri-operative anti-epileptic drugs in patients with newly diagnosed high grade malignant glioma: a single center experience. J. Neurooncol. 2010; 96 (3): 403-408.
2. Oberndorfer S, Schmal T, Lahrmann H, Urbanits S, Lindner K, Grisold W. The frequency of seizures in patients with primary brain tumors or cerebral metastases. An evaluation from the Ludwig Boltzmann Institute of Neuro-Oncology and the Department of Neurology, Kaiser Franz Josef Hospital, Vienna. Wien. Klin. Wochenschr. 2002; 114 (21-22): 911-916.
3. Wick W, Menn O, Meisner C etal. Pharmacotherapy of epileptic seizures in glioma patients: who, when, why and how long? Onkologie 2005; 28 (8-9): 391-396.
4. Sirven JI, Wingerchuk DM, Drazkowski JF, Lyons MK, Zimmerman RS. Seizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin. Proc. 2004; 79 (12): 1489-1494.
5. Glantz MJ, Cole BF, Forsyth PA etal. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 54 (10): 1886-1893.
6. Louis DN, Ohgaki H, Wiestler OD etal. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114 (2): 97-109.
7. Perucca P, Gilliam FG. Adverse effects of antiepileptic drugs. Lancet Neurol. 2012; 11 (9): 792-802.
8. Buckner JC, Brown PD, O'Neill BP, Meyer FB, Wetmore CJ, Uhm JH. Central nervous system tumors. Mayo Clin. Proc. 2007; 82 (10): 1271-1286.
9. Moots PL, Maciunas RJ, Eisert DR, Parker RA, Laporte K, Abou-Khalil B. The course of seizure disorders in patients with malignant gliomas. Arch. Neurol. 1995; 52 (7): 717-724.
10. van Breemen MS, Rijsman RM, Taphoorn MJ, Walchenbach R, Zwinkels H, Vecht CJ. Efficacy of anti-epileptic drugs in patients with gliomas and seizures. J. Neurol. 2009; 256 (9): 1519-1526.
11. Chang SM, Parney IF, Huang W etal. Patterns of care for adults with newly diagnosed malignant glioma. JAMA 2005; 293 (5): 557-564.
12. Schaller B, Ruegg SJ. Brain tumor and seizures: pathophysiology and its implications for treatment revisited. Epilepsia 2003; 44 (9): 1223-1232.
13. Oberndorfer S, Piribauer M, Marosi C, Lahrmann H, Hitzenberger P, Grisold W. P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J. Neurooncol. 2005; 72 (3): 255-260.
14. Jaeckle KA, Ballman K, Furth A, Buckner JC. Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma. Neurology 2009; 73 (15): 1207-1213.
15. Weller M, Gorlia T, Cairncross JG etal. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology 2011; 77 (12): 1156-1164.
16. Yuan Y, Yunhe M, Xiang W etal. P450 enzyme-inducing and non-enzyme-inducing antiepileptic drugs for seizure prophylaxis after glioma resection surgery: a meta-analysis. Seizure 2014; 23 (8): 616-621.
17. Bjornsson E. Hepatotoxicity associated with antiepileptic drugs. Acta Neurol. Scand. 2008; 118 (5): 281-290.
18. Handoko KB, van Puijenbroek EP, Bijl AH etal. Influence of chemical structure on hypersensitivity reactions induced by antiepileptic drugs: the role of the aromatic ring. Drug Saf. 2008; 31 (8): 695-702.
19. Cheung YK, Cheng SH, Chan EJ, Lo SV, Ng MH, Kwan P. HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese. Epilepsia 2013; 54 (7): 1307-1314.
20. Chung WH, Hung SI, Hong HS etal. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 428 (6982): 486.
21. Miller JW. Of race, ethnicity, and rash: the genetics of antiepileptic drug-induced skin reactions. Epilepsy Curr. 2008; 8 (5): 120-121.
22. Neuman MG, Cohen L, Nanau RM, Hwang PA. Genetic and immune predictors for hypersensitivity syndrome to antiepileptic drugs. Transl. Res. 2012; 159 (5): 397-406.
23. Wang XQ, Lang SY, Shi XB, Tian HJ, Wang RF, Yang F. Cross-reactivity of skin rashes with current antiepileptic drugs in Chinese population. Seizure 2010; 19 (9): 562-566.
24. Riva M. Brain tumoral epilepsy: a review. Neurol. Sci. 2005; 26 (Suppl 1): S40-42.
25. Elisevich K. Tumor associated epilepsy. In: Lichtor T (ed.). Clinical Management and Evolving Novel Therapeutic Strategies for Patients with Brain Tumors, 1st edn. New York: InTech, 2013; 225-246.
26. Rosati A, Marconi S, Pollo B etal. Epilepsy in glioblastoma multiforme: correlation with glutamine synthetase levels. J. Neurooncol. 2009; 93 (3): 319-324.
27. Herrmann T, Knorr A, Dorner K. The RTOG/EORTC classification criteria for early and late radiation reactions. Radiobiol. Radiother. (Berl.) 1987; 28 (4): 519-528.
28. Hottinger AF, Yoon H, DeAngelis LM, Abrey LE. Neurological outcome of long-term glioblastoma survivors. J. Neurooncol. 2009; 95 (3): 301-305.
29. Federal Food and Drug Administration Alert. Information for healthcare professionals carbamazepine (marketed as Carbatrol, Equetro, Tegretol and generics). 2007. [Cited 14 Sep 2014.] Available from URL: http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm124718.htm